CAMBRIDGE, Mass & RESEARCH TRIANGLE PARK, N.C. & SEOUL, South Korea--(BUSINESS WIRE)--Hudson Therapeutics announced that Shaperon (KOSDAQ 378800, CEO Seung-Yong Seong), an innovative biopharmaceutical company specializing in immune therapeutics, has signed a Memorandum of Understanding (MOU) with Dong-A ST (KOSPI 170900, CEO Min-Young Kim) for the development of nanobody-based new drugs..

北卡罗来纳州剑桥与研究三角公园（CAMBRIDGE，Mass＆RESEARCH TRIANGLE PARK，N.C.）和韩国首尔（SEOUL），Hudson Therapeutics宣布，Shaperon（KOSDAQ 378800，CEO Seung Yong Seong）是一家专门从事免疫治疗的创新生物制药公司，已与Dong-a ST（KOSPI 170900，CEO Min Young Kim）签署了一份谅解备忘录（MOU），以开发基于纳米体的新药。。

A representative from Shaperon stated, 'This MOU aims to leverage Shaperon's nanobody development platform technology and Dong-A ST's expertise in antibody commercialization to increase development speed and commercialization potential.' Additionally, they stated, 'We plan to select the most effective nanobodies in mouse models with human tumor transplants by the end of this year.'.

Shaperon的一位代表表示，“本谅解备忘录旨在利用Shaperon的纳米体开发平台技术和Dong-A ST在抗体商业化方面的专业知识，以提高开发速度和商业化潜力。”此外，他们表示，“我们计划在今年年底之前在人类肿瘤移植的小鼠模型中选择最有效的纳米体。”。

Since 2021, the two companies have collaborated on developing triple nanobody antibodies for cancer treatment. This involves using nanobodies to bring killer T cells and cancer cells into proximity by binding to targets on both cell types. Shaperon will advance nanobody development using its full-cycle platform, while Dong-A ST will leverage its antibody commercialization expertise for global biopharmaceutical development..

自2021年以来，两家公司一直合作开发用于癌症治疗的三重纳米抗体。这涉及使用纳米体通过结合两种细胞类型上的靶标使杀伤性T细胞和癌细胞接近。Shaperon将使用其全周期平台推进纳米体开发，而Dong-A ST将利用其抗体商业化专业知识进行全球生物制药开发。。

Nanobodies, about one-tenth the size of conventional antibodies, are gaining attention for next-generation immune checkpoint inhibitors due to their high stability, solubility, and production yield. Shaperon, the only domestic company with a full-cycle platform for nanobody production, development, and analysis from alpaca immunization, is developing a diverse pipeline targeting inflammation and cancer, including immune checkpoint dual antibodies and nanobody-based therapeutics..

纳米抗体的大小约为常规抗体的十分之一，由于其高稳定性，溶解度和产量，正在受到下一代免疫检查点抑制剂的关注。Shaperon是国内唯一一家拥有羊驼免疫纳米抗体生产、开发和分析全周期平台的公司，正在开发针对炎症和癌症的多样化管道，包括免疫检查点双重抗体和基于纳米抗体的治疗剂。。

Shaperon, the only domestic company with a full-cycle platform for nanobody production, development, and analysis from alpaca immunization, is developing a diverse pipeline targeting inflammation and cancer. This includes immune checkpoint dual antibodies and nanobodies for infectious diseases. Shaperon is also exploring nanobody-based protein therapeutics, such as antibody-drug conjugates (ADCs) and radiopharmaceutical therapies.

Shaperon是国内唯一一家拥有羊驼免疫纳米体生产，开发和分析全周期平台的公司，正在开发针对炎症和癌症的多样化管道。这包括用于传染病的免疫检查点双抗体和纳米抗体。Shaperon还在探索基于纳米体的蛋白质疗法，例如抗体-药物偶联物（ADC）和放射性药物疗法。

Recently, they published preclinical results on influenza-targeting nanobodies and presented anti-cancer PDL1-CD47 dual nanobodies at the AACR, gaining recognition for their technological capabilities..

最近，他们发表了针对流感的纳米抗体的临床前结果，并在AACR上展示了抗癌PDL1-CD47双纳米抗体，其技术能力得到了认可。。

Janice Marie McCourt of Hudson Therapeutics in the US stated, “We have numerous global biotech companies that we met at BIO, Bio Europe, Bio Asia and the Pharm Summit conferences who are signing confidentiality agreements to license the current preclinical immune-oncology bispecific lead program, along with collaborating on Shaperon's nanobody development platform to create bispecific and trispecific nanobody antibodies in orphan indications, immunology, inflammation, oncology and infectious disease targets that are first-in-class or best-in-class assets with significant commercial potential.

美国哈德逊治疗公司（Hudson Therapeutics）的Janice Marie McCourt表示：“我们在生物、生物欧洲、生物亚洲和药学峰会上遇到了许多全球生物技术公司，他们正在签署保密协议，以许可当前的临床前免疫肿瘤学双特异性领先项目，并与Shaperon的纳米体开发平台合作，在孤儿适应症、免疫学、炎症、肿瘤学和传染病目标中创建双特异性和三特异性纳米抗体，这些目标是一流或一流的资产，具有巨大的商业潜力。

We are so excited that the global R&D scientists and clinicians are excited to collaborate with us and create an impact focused on patients with significant unmet needs.”.

我们非常兴奋，全球研发科学家和临床医生都很兴奋与我们合作，并为那些需求严重未满足的患者创造影响。”。

ABOUT SHAPERON

关于SHAPERON

Shaperon is a clinical-stage biotech company developing novel inflammasome inhibitors. Its unique mechanism of action of GPCR19-P2X7 modulation suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α by controlling both the priming and activation phases of the inflammasome, whereas conventional approaches are designed to suppress only the activation phase.

Shaperon是一家开发新型炎性体抑制剂的临床阶段生物技术公司。它独特的GPCR19-P2X7调节作用机制通过控制炎性体的启动和激活阶段来抑制广泛的炎性细胞因子，包括IL-1β，IL-18，IL-6和TNF-α，而常规方法旨在仅抑制激活阶段。

With this unique and novel modality, which is best suited to address complex immune-mediated inflammatory disorders, Shaperon is currently developing multiple clinical programs in atopic dermatitis, Alzheimer’s disease, and COVID-19 pneumonia in addition to pre-clinical pipelines, including NASH and obesity programs..

凭借这种最适合解决复杂的免疫介导的炎症性疾病的独特而新颖的方式，Shaperon目前正在开发特应性皮炎，阿尔茨海默氏病和新型冠状病毒肺炎的多种临床计划，以及临床前管道，包括NASH和肥胖计划。。

ABOUT HUDSON THERAPEUTICS

关于HUDSON THERAPEUTICS

Hudson Therapeutics, a US subsidiary of Shaperon, was founded and incorporated in the US in 2023 to lead global clinical trials, investor relations, commercial strategy, and business development of assets from Shaperon. Hudson also plans to develop Shaperon's early-stage assets in the future.

Hudson Therapeutics是Shaperon的美国子公司，于2023年在美国成立并注册成立，负责领导Shaperon的全球临床试验、投资者关系、商业战略和资产业务开发。哈德逊还计划在未来开发Shaperon的早期资产。